Skip to main content
U.S. flag

An official website of the United States government

Debate: Albumin administration should be avoided in the critically ill

Published by National Institutes of Health | U.S. Department of Health & Human Services | Catalog Last Checked: September 07, 2025 at 08:11 AM | Dataset Last Updated: September 06, 2025
The benefit of albumin administration in the critically ill patient is unproven. Epidemiological evidence suggests that there is an increase in death among patients with burns, hypoalbuminaemia, and hypotension treated with human albumin solution (HAS). In critical illness, hypoalbuminaemia is a result of transcapillary leak, decreased synthesis, large volume body fluid losses and dilution caused by fluid resuscitation. When treating patients with hypoalbuminaemia, efforts must be centred around correction of the underlying disorder rather than reversal of hypoalbuminaemia. Problems with using albumin arise because it is an expensive blood product, and can result in systemic changes that include cardiovascular, haematological, renal, pulmonary, and immunological effects.

Resources

1 resource available

  • Official Government Data Source

    TEXT/HTML

Find Related Datasets

Search by Tags

Click any tag below to search for similar datasets

data.gov

An official website of the GSA's Technology Transformation Services

Looking for U.S. government information and services?
Visit USA.gov